What is the recommended management for a patient with an upper gastrointestinal bleed?

Management of Upper Gastrointestinal Bleeding

Initiate immediate resuscitation for hemodynamically unstable patients, perform early endoscopy within 24 hours, use Glasgow-Blatchford score ≤1 to identify very low-risk patients for outpatient management, transfuse at hemoglobin <7 g/dL (8 g/dL if cardiovascular disease), and provide high-dose PPI therapy after endoscopic hemostasis for high-risk lesions. 1

Initial Resuscitation and Risk Stratification

Begin with aggressive fluid resuscitation for any patient showing hemodynamic instability (hypotension, tachycardia, altered mental status). This is fundamental and non-negotiable 1.

Use the Glasgow-Blatchford Score (GBS) immediately upon presentation. Patients with GBS ≤1 are at very low risk for rebleeding or mortality and can be safely discharged with outpatient endoscopy rather than admission 1. Do not use the AIMS65 score for this purpose—it lacks sufficient evidence 1.

Transfusion Strategy

• Without cardiovascular disease: Transfuse when hemoglobin drops below 7 g/dL (70 g/L) 1
• With cardiovascular disease: Use a higher threshold (7-8 g/dL or 70-80 g/L) 1

This restrictive strategy improves outcomes compared to liberal transfusion policies.

Pre-Endoscopic Pharmacologic Management

For Suspected Peptic Ulcer Disease

• Administer PPI therapy (can downstage lesions and reduce need for intervention, but do not delay endoscopy) 1
• Give erythromycin infusion before endoscopy to improve visualization 1
• Do NOT use H2-receptor antagonists—they are ineffective 1
• Do NOT use somatostatin or octreotide routinely for ulcer bleeding 1

For Suspected Variceal Bleeding (Cirrhosis)

• Start prophylactic antibiotics immediately before endoscopy 1
• Initiate vasoactive drugs (octreotide, terlipressin, or somatostatin) before endoscopy 1

Anticoagulation Management

Do not delay endoscopy in patients on anticoagulants (warfarin or DOACs). Proceed with endoscopy and hemostatic therapy as needed 1.

Endoscopic Management Timing and Approach

Perform endoscopy within 24 hours of presentation for all hospitalized patients 1. Earlier intervention (within 12 hours) does not improve outcomes compared to the 24-hour window, so urgent endoscopy is not routinely recommended unless there is ongoing massive bleeding 1.

Endoscopic Therapy by Lesion Type

High-Risk Peptic Ulcer Stigmata (Active Bleeding or Visible Vessel)

For actively bleeding ulcers (spurting or oozing):

• Use combination therapy: epinephrine injection PLUS a second modality (contact thermal therapy, clips, or sclerosant injection) 1
• Never use epinephrine injection alone—it provides suboptimal efficacy 1

Recommended endoscopic modalities:

• Thermocoagulation (bipolar, heater probe) or sclerosant injection (strong recommendation) 1
• Through-the-scope clips (conditional recommendation) 1
• No single thermal method is superior to another 1

For refractory bleeding:

• Consider TC-325 hemostatic powder as temporizing therapy when conventional methods fail, but NOT as monotherapy 1
• Consider over-the-scope clips (OTSCs) for recurrent bleeding after initial hemostasis 1

Low-Risk Stigmata

Do NOT perform endoscopic therapy for clean-based ulcers or flat pigmented spots—these do not benefit from intervention 1.

Adherent Clots

Attempt targeted irrigation to dislodge the clot. If a high-risk lesion is revealed underneath, treat it. The role of empiric therapy for adherent clots is controversial; intensive PPI therapy alone may suffice 1.

Nonvariceal Nonpeptic Ulcer Bleeding (Newer 2025 Guidance)

The most recent 2025 Canadian guidelines provide specific recommendations for non-ulcer causes 2:

Malignant tumors with active bleeding:

• Use topical hemostatic agents over conventional therapy
• Administer oncologic therapy after endoscopic intervention 2

Mallory-Weiss tears with active bleeding:

• Use endoscopic band ligation or through-the-scope clips over epinephrine alone
• Do NOT treat non-bleeding tears with visible vessels, clots, or pigmented spots 2

Dieulafoy's lesions:

• Use mechanical modalities (band ligation or clips), contact thermocoagulation, or sclerosants over epinephrine alone 2

Gastric antral vascular ectasia (GAVE):

• Use endoscopic band ligation over argon plasma coagulation 2

Post-Endoscopic Pharmacologic Management

For High-Risk Peptic Ulcer Disease After Successful Hemostasis

Administer high-dose PPI therapy (strong recommendation) 1:

• Preferred regimen: IV bolus (80 mg) followed by continuous infusion (8 mg/hour) for 72 hours 1
• Alternative regimens: Twice-daily IV bolus or twice-daily oral PPI 1

After 72 hours, transition to twice-daily oral PPI for 14 days, then once daily 1. Continue single daily-dose oral PPI for duration dictated by underlying cause 1.

For Adherent Clots Not Treated Endoscopically

High-dose PPI therapy is recommended 1.

Management of Rebleeding

Routine second-look endoscopy is NOT recommended 1.

For clinical rebleeding:

1. First attempt: Repeat endoscopic therapy (generally recommended) 1
2. Consider over-the-scope clips for recurrent ulcer bleeding 1
3. If second endoscopic attempt fails: Proceed to transcatheter angiographic embolization (TAE) 1
4. Surgery is indicated only when TAE is unavailable or has failed 1

Post-Hemostasis Hospital Management

• Feed patients within 24 hours after endoscopy if low-risk 1
• Hospitalize high-risk patients for at least 72 hours after endoscopic hemostasis 1
• Test for Helicobacter pylori in all peptic ulcer patients and provide eradication therapy if positive, with confirmation of eradication 1
• Repeat negative H. pylori tests obtained during acute bleeding, as they may be falsely negative 1

Resumption of Antithrombotic Therapy

Aspirin for Secondary Cardiovascular Prophylaxis

Do not interrupt low-dose aspirin during acute bleeding. If interrupted, restart as soon as possible, preferably within 3-5 days 1.

Anticoagulation

Resume anticoagulation as soon as bleeding is controlled, preferably within or soon after 7 days, based on thromboembolic risk 1. Remember that DOACs have rapid onset compared to warfarin.

PPI Co-therapy

Use PPI therapy in patients on antiplatelet or anticoagulant therapy with previous ulcer bleeding 1.

Common Pitfalls to Avoid

• Do not use epinephrine injection as monotherapy—always combine with another modality
• Do not perform urgent (<12 hours) endoscopy routinely—it doesn't improve outcomes over early (24-hour) endoscopy
• Do not use promotility agents routinely—only erythromycin has evidence for improving visualization
• Do not delay endoscopy in anticoagulated patients—proceed with appropriate reversal strategies if needed
• Do not use TC-325 powder as sole therapy—it's for temporizing or rescue only
• Do not forget to test and treat H. pylori—this prevents recurrence